Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Add as a preferred source on Google
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
